BerandaDUL • ETR
add
Alnylam Pharmaceuticals, Inc.
Tutup sebelumnya
€281,80
Rentang hari
€279,60 - €284,90
Rentang tahun
€263,50 - €417,40
Kapitalisasi pasar
44,86Â M USD
Volume Rata-Rata
15,00
Rasio P/E
-
Hasil dividen
-
Bursa utama
NASDAQ
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 1,10Â M | 84,95% |
Biaya operasional | 697,59Â jt | 17,14% |
Penghasilan bersih | 186,42Â jt | 322,56% |
Margin laba bersih | 16,99 | 220,33% |
Penghasilan per saham | 1,25 | 1.983,33% |
EBITDA | 145,22Â jt | 259,60% |
Tarif pajak efektif | -15,69% | — |
Neraca
Total aset
Total liabilitas
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 2,91Â M | 7,94% |
Total aset | 4,97Â M | 17,13% |
Total liabilitas | 4,18Â M | 0,10% |
Total ekuitas | 789,18 jt | — |
Saham yang beredar | 132,62 jt | — |
Harga terhadap nilai buku | 47,28 | — |
Tingkat pengembalian aset | 6,71% | — |
Tingkat pengembalian modal | 9,73% | — |
Arus Kas
Perubahan kas bersih
| (USD) | Des 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | 186,42Â jt | 322,56% |
Kas dari operasi | 163,56Â jt | 272,78% |
Kas dari investasi | -37,17Â jt | 29,76% |
Kas dari pembiayaan | 45,32Â jt | 46,20% |
Perubahan kas bersih | 166,00Â jt | 224,03% |
Arus kas bebas | -44,92Â jt | 40,57% |
Tentang
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list. Wikipedia
Didirikan
14 Jun 2002
Situs
Karyawan
2.500
